NOBIVAC® Lyme Vaccine

One-of-a-kind protection

The only vaccine licensed to protect against inflammation and pathology of subclinical arthritis and its potential long-term repercussions^1,5

Product Description

Lyme vaccine designed to target the 2 key outer surface proteins (Osps) involved in disease transmission for a full level of protection
Proven to induce borreliacidal antibodies that bind to OspA and OspC, forming a complex that attacks the cell membrane and kills Borrelia burgdorferi ^1,5
Proven to help prevent clinical disease such as arthritis – as well as at the subclinical level ⁵
Highly effective: no serologic evidence of exposure to Borrelia burgdorferi ⁵

NOBIVAC® LYME PROVIDES PROVEN PROTECTION FOR CANINES

Our commitment to leadership is vaccine development that provides comprehensive protection against Lyme disease.

product Label

Overview

Indications:

Shown to be effective for vaccination of healthy dogs 8 weeks of age or older against Borrelia burgdorferi. Duration of Immunity is at least 1 year. Also been shown to be effective against subclinical arthritis caused by Borrelia burgdorferi. Recommended for use in healthy dogs 8 weeks of age or older.

NOBIVAC^® LYME IS A SAFE CHOICE

Proven safe and well tolerated in a field safety trial of more than 600 dogs
99.3% reaction-free
Since 2009, Nobivac^® Lyme has been safely administered to over 4 million dogs

ADMINISTRATION AND DOSAGE

Subcutaneous injection
Two 1 mL doses given 2 to 4 weeks apart
Duration of immunity is at least 1 year
Available in a 25 x 1 mL dose presentation

DISEASE INFORMATION

Canine Lyme Disease

Efficacy

ANTIBODY ACTIVITY

THE BORRELIACIDAL DIFFERENCE

Only Nobivac^® Lyme induces borreliacidal activity against both OspA and OspC^1,5,80 Not all antibody responses are the same.

“Multi-Osp protection” that induces antibodies against Osps other than OspA and OspC has not been shown to be relevant^5,29,30
Other Lyme vaccines may induce antibodies against OspC, but they are not borreliacidal—meaning they don’t kill Borrelia burgdorferi
- As a result, vaccines that only induce borreliacidal antibodies against OspA provide incomplete protection once OspC becomes the dominant protein expressed in the tick
Only Nobivac® Lyme induces OspC borreliacidal antibodies that kill spirochetes in the tick midgut, those migrating from the midgut to the tick’s salivary glands, and those introduced into the dog⁸⁰

COMPETITIVE COMPARISON

ONLY NOBIVAC^® LYME OFFERS POWERFUL COMPARATIVE BENEFITS AND PROVEN SAFETY.

PREVENTS JOINT ABNORMALITIES

NOBIVAC^® LYME IS SHOWN TO BE EFFECTIVE AGAINST SUBCLINICAL ARTHRITIS, IN ADDITION TO CLINICAL DISEASE⁵

Following vaccination with Nobivac® Lyme:

No Borrelia burgdorferi were found in the joint
No joint inflammation, stiffness, or lameness were observed⁵
- 40% of control dogs developed chronic joint inflammation⁵
- 27% of control dogs developed joint stiffness or lameness⁵
Dogs exhibited no signs of Lyme disease–associated joint abnormalities⁵

TICK CHALLENGE STUDY

NOBIVAC® LYME IS HIGHLY EFFECTIVE IN KILLING BORRELIA BURGDORFERI AND PREVENTING INFECTION5

Tick challenge study confirms effectiveness.⁵

Following vaccination with Nobivac®, no B. burgdorferi were found.

The tick challenge study was a placebo-controlled trial involving thirty 8-week-old puppies. Dogs were challenged 3 weeks following second vaccination.

Professional Resources and Educational Materials

Keep your clinic and staff informed and aware of diseases and outbreaks.

View More Nobivac® Resources

Brochure

Lyme Disease Pet Parent Guide

Printable brochure to educate pet parents about their dog’s risk for Canine Lyme Disease. What is Lyme disease? What are the signs of Lyme disease? How serious is Lyme disease?

Download

References: